Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EL-M study: Elotuzumab + lenalidomide maintenance after autologous stem cell transplantation in multiple myeloma
jRCTs031190026Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elotuzumab and lenalidomide in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoint: Rate of VGPR + CR + sCR at one year after starting maintenance therapy. Started Dec 2019; status: completed.
02
Drugs
elotuzumablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs031190026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190026.